Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | DDX3X | O00571 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675624 | 0.88 | MEN1 (0.59) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL14222078 | 0.88 | MEN1 (0.59) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL5701006 | 0.86 | ITGA4 (0.61) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL14500970 | 0.86 | MEN1 (0.56) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL4683165 | 0.86 | ITGA4 (0.67) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL6597529 | 0.86 | MEN1 (0.56) | MEN1KMT2AITGB1ITGA4MAPT | |
| SCHEMBL5274777 | 0.85 | MEN1 (0.55) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL6136413 | 0.84 | ITGB1 (0.66) | MEN1KMT2AGAAITGB1ITGA4 | |
| SCHEMBL5852144 | 0.82 | LPAR1 (0.71) | MEN1KMT2AGAAMAPTSMN1; SMN2 | |
| SCHEMBL7868788 | 0.82 | ITGB1 (0.60) | MEN1KMT2AGAAITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414444-B1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1381595-B1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6794517-B2 | AS CHEMICAL INTERMEDIATE TO FORM DRUGS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1414444-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1381595-A1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-6680333-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIALLERGENS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| EP-1183241-B1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003011288-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| US-20020183374-A1 | Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072557-A1 | BIS(TRIFLUOROMETHYL)HYDANTOINS AS INTERMEDIATES FOR PHARMACEUTICALLY ACTIVE INGREDIENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| US-6399643-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-1183241-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069831-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | VCAM1, ITGA4, ITGA1 | MEN1 4355/4885KMT2A 1766/4885GAA 2950/4885 |
| US-20020183374-A1 | Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients | HRH1, ALDH7A1, HRH4 | MEN1 921/4885KMT2A 1248/4885GAA 1526/4885 |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | MEN1 4652/4885KMT2A 1692/4885GAA 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.